Evropska unija - romunščina - EMA (European Medicines Agency)

bayer ag - octocog alfa - hemofilia a - hemostatice - tratamentul și profilaxia hemoragiilor la pacienții cu hemofilie a (deficit congenital de factor viii). iblias poate fi utilizat pentru toate grupele de vârstă.

Evropska unija - romunščina - EMA (European Medicines Agency)

bayer ag  - octocog alfa - hemofilia a - hemostatice - tratamentul și profilaxia hemoragiei la pacienții cu hemofilie a (deficit congenital de factor viii). acest preparat nu conține factorul von willebrand și este, prin urmare, nu este indicat în boala von willebrand.

Evropska unija - romunščina - EMA (European Medicines Agency)

mylan pharmaceuticals limited - darunavir - infecții cu hiv - antivirale pentru uz sistemic - darunavir, co-administered with low dose ritonavir is indicated in combination with other antiretroviral medicinal products for the treatment of patients with human immunodeficiency virus (hiv-1) infection (see section 4. darunavir mylan 75 mg, 150 mg, 300 mg and 600 mg tablets may be used to provide suitable dose regimens (see section 4. 2):pentru tratamentul infecției cu hiv-1 în tratament antiretroviral (art)-adult cu experiență de pacienți, inclusiv cei care au fost extrem de pre-tratate. pentru tratamentul infecției cu hiv-1 la pacienții copii și adolescenți începând cu vârsta de 3 ani și de cel puțin 15 kg greutate corporala. În decizia de a iniția tratamentul cu darunavir, administrat concomitent cu o doză mică de ritonavir, trebuie acordată o atenție deosebită la tratament istoria individuală a fiecărui pacient și modele de mutații asociate cu diferiți agenți. genotypic or phenotypic testing (when available) and treatment history should guide the use of darunavir (see sections 4. 2, 4. 4 și 5. darunavir, administrat concomitent cu o doză mică de ritonavir, este indicat, în asociere cu alte medicamente antiretrovirale pentru tratamentul pacienților infectați cu virusul imunodeficienței umane (hiv-1) infecție.  darunavir co-administered with cobicistat is indicated in combination with other antiretroviral medicinal products for the treatment of human immunodeficiency virus (hiv-1) infection in adults and adolescents (aged 12 years and older, weighing at least 40 kg) (see section 4.  darunavir mylan 400 mg and 800 mg tablets may be used to provide suitable dose regimens for the treatment of hiv-1 infection in adult and paediatric patients from the age of 3 years and at least 40 kg body weight who are: antiretroviral therapy (art)-naïve (see section 4.  art-experienced with no darunavir resistance associated mutations (drv-rams) and who have plasma hiv-1 rna < 100,000 copies/ml and cd4+ cell count ≥ 100 cells x 10⁶/l. În decizia de a iniția tratamentul cu darunavir în astfel de artĂ cu pacienți, genotipice de testare ar trebui să ghideze utilizarea de darunavir (a se vedea secțiunile 4. 2, 4. 3, 4. 4 și 5.

Evropska unija - romunščina - EMA (European Medicines Agency)

janssen-cilag international nv - darunavir - infecții cu hiv - antivirale pentru uz sistemic - prezista, co administered with low dose ritonavir is indicated in combination with other antiretroviral medicinal products for the treatment of human immunodeficiency virus (hiv 1) infection in adult and paediatric patients from the age of 3 years and at least 15 kg body weight. prezista, co administered with cobicistat is indicated in combination with other antiretroviral medicinal products for the treatment of human immunodeficiency virus (hiv 1) infection in adults and adolescents (aged 12 years and older, weighing at least 40 kg). in deciding to initiate treatment with prezista co administered with cobicistat or low dose ritonavir, careful consideration should be given to the treatment history of the individual patient and the patterns of mutations associated with different agents. genotypic or phenotypic testing (when available) and treatment history should guide the use of prezista. prezista, co administered with low dose ritonavir is indicated in combination with other antiretroviral medicinal products for the treatment of patients with human immunodeficiency virus (hiv 1) infection. prezista 75 mg, 150 mg, and 600 mg tablets may be used to provide suitable dose regimens:for the treatment of hiv 1 infection in antiretroviral treatment (art) experienced adult patients, including those that have been highly pre treated. for the treatment of hiv 1 infection in paediatric patients from the age of 3 years and at least 15 kg body weight. in deciding to initiate treatment with prezista co administered with low dose ritonavir, careful consideration should be given to the treatment history of the individual patient and the patterns of mutations associated with different agents. genotypic or phenotypic testing (when available) and treatment history should guide the use of prezista. prezista, co administered with low dose ritonavir is indicated in combination with other antiretroviral medicinal products for the treatment of patients with human immunodeficiency virus (hiv 1) infection. prezista, co administered with cobicistat is indicated in combination with other antiretroviral medicinal products for the treatment of human immunodeficiency virus (hiv 1) infection in adults and adolescents (aged 12 years and older, weighing at least 40 kg). prezista 400 mg and 800 mg tablets may be used to provide suitable dose regimens for the treatment of hiv 1 infection in adult and paediatric patients from the age of 3 years and at least 40 kg body weight who are:antiretroviral therapy (art) naïve. art experienced with no darunavir resistance associated mutations (drv rams) and who have plasma hiv 1 rna < 100,000 copies/ml and cd4+ cell count ≥ 100 cells x 106/l. in deciding to initiate treatment with prezista in such art experienced patients, genotypic testing should guide the use of prezista.

Romunija - romunščina - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

hexal ag - germania - fentanylum - plasture transdermic - 25µg/h - alcaloizi naturali din opiu derivati de fenilpiperidina

Romunija - romunščina - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

hexal ag - germania - fentanylum - plasture transdermic - 50µg/h - alcaloizi naturali din opiu derivati de fenilpiperidina

Romunija - romunščina - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

hexal ag - germania - fentanylum - plasture transdermic - 75µg/h - alcaloizi naturali din opiu derivati de fenilpiperidina

Romunija - romunščina - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

hexal ag - germania - fentanylum - plasture transdermic - 100µg/h - alcaloizi naturali din opiu derivati de fenilpiperidina

Romunija - romunščina - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

ferrer internacional, s.a. - spania - acid acetylsalicylicum+atorvastatinum+ramiprilum - caps. - 100mg/20mg/2,5mg - hipolipemiante, combinatii inhibitori de hmg coa reductaza, alte combinatii